Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 | O60894 | 1/20 | 0.78 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.78 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.78 |
| ▸ | CALCR | P30988 | 1/20 | 0.78 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.78 |
| ▸ | NPY2R | P49146 | 12/20 | 0.66 |
| ▸ | PRLHR | P49683 | 4/20 | 0.62 |
| ▸ | INSR | P06213 | 1/20 | 0.62 |
| ▸ | GLP1R | P43220 | 1/20 | 0.60 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amylin SCHEMBL29351499 | 0.98 | RAMP1 (0.75) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Davalintide SCHEMBL29533482 | 0.89 | RAMP1 (0.77) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Pramlintide SCHEMBL29355376 | 0.88 | RAMP1 (1.00) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Pramlintide SCHEMBL29354060 | 0.87 | RAMP1 (0.99) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL30078470 | 0.87 | RAMP1 (0.91) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29511605 | 0.85 | RAMP1 (0.71) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| Davalintide SCHEMBL29377013 | 0.83 | RAMP1 (0.85) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29357151 | 0.83 | RAMP1 (0.68) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL31692974 | 0.81 | RAMP1 (0.82) | RAMP1RAMP2RAMP3CALCRCALCRL | |
| SCHEMBL29382043 | 0.79 | GLP1R (0.80) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1726 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074076-A | Peptides for detection of amyloid fibril aggregates | 乌特勒支大学 | 2026-05-22 | — | — | CN | claimed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4705280-A1 | DIARYL UREA-BASED COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DIABETES MELLITUS AND NEURODEGENERATIVE DISEASE | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705326-A1 | GENE THERAPY FOR TREATMENT OF PROTEIN MISFOLDING DISEASES | Research Institute at Nationwide Children's Hospital (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260043815-A1 | METHODS FOR DETECTING B-ISOX PRECIPITATES OR CAPTURED PROTEINS AS BIOFLUID BIOMARKERS FOR DIFFERENTIAL DIAGNOSTIC, PATHOPHYSIOLOGY MONITORING OR PRESYMPTOMATIC DIAGNOSTIC OF PREDIABETES, DIABETES AND CANCERS | YEEFAN MED INC (US) | 2026-02-12 | — | — | US | claimed |
| EP-4686725-A1 | AMYLOID INHIBITORY PEPTIDES | Technische Universität München, in Vertretung des Freistaats Bayern (DE) | 2026-02-04 | — | — | EP | claimed |
| US-12502114-B2 | Amyloid fibers based electrodes | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2025-12-23 | — | — | US | claimed |
| US-20250321237-A1 | ASSAY FOR RAPID PROTEIN MULTIMER DETECTION, CHARACTERIZATION AND QUANTIFICATION | WESTERN MICHIGAN UNIVERSITY HOMER STRYKER M.D. SCHOOL OF MEDICINE (US) | 2025-10-16 | — | — | US | claimed |
| EP-4611818-A2 | ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS | Avilar Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250270319-A1 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | ALECTOR LLC (US) | 2025-08-28 | — | — | US | claimed |
| WO-2022094630-A1 | SAP FC FUSION PROTEINS AND METHODS OF USE | ATTRALUS, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| US-20220123377-A1 | CONVECTION-ENHANCED ELECTROCHEMICAL ENERGY STORAGE DEVICES AND RELATED METHODS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-04-21 | — | — | US | claimed |
| US-20220119468-A1 | AMYLOID PEPTIDE VARIANTS | LOYOLA MARYMOUNT UNIVERSITY | 2022-04-21 | — | — | US | claimed |
| CN-114341181-A | anti-MS 4A4A antibodies and methods of use thereof | 艾莱克特有限责任公司 | 2022-04-12 | — | — | CN | claimed |
| US-20220090020-A1 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-03-24 | — | — | US | claimed |
| CN-108884126-B | Compounds for treating eye disorders or diseases | 广州康睿生物医药科技股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-20220040145-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. | 2022-02-10 | — | — | US | claimed |
| EP-3946385-A1 | THE TREATMENT OF PROTEIN AGGREGATION DISEASES | Pharmakure Limited (GB) | 2022-02-09 | — | — | EP | claimed |
| WO-2022026933-A2 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026932-A2 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220090020-A1 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | IAPP, PNLIP, GPR119 | RAMP1 3743/4885RAMP2 3661/4885RAMP3 1955/4885 |
| US-20220040145-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | APP, PSEN1, BACE1 | RAMP1 2362/4885RAMP2 3077/4885RAMP3 1755/4885 |
| US-20260043815-A1 | METHODS FOR DETECTING B-ISOX PRECIPITATES OR CAPTURED PROTEINS AS BIOFLUID BIOMARKERS FOR DIFFERENTIAL DIAGNOSTIC, PATHOPHYSIOLOGY MONITORING OR PRESYMPTOMATIC DIAGNOSTIC OF PREDIABETES, DIABETES AND CANCERS | IGFBP4, RBP4, IGFBP3 | RAMP1 3621/4885RAMP2 3625/4885RAMP3 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.